Key Drivers
- Strong Cash Flow
- High Leverage
- Improving Liquidity
AIAI Summary
COLL now looks less like a cheap specialty pharma name and more like a cash-generating growth platform, but the investment case hinges on whether AZSTARYS integration and ADHD franchise momentum can compound without leverage becoming a constraint; the key takeaway is that execution, not valuation, will determine upside from here.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •High Leverage
- •Improving Liquidity
COLL is profitable and cash-generative with improving liquidity, but its investment case is tempered by high leverage, modest interest coverage, and a heavy intangible asset load.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Fast rebound
- •Stretched rally
COLL turned bullish over the last month with a clear sequence of higher lows and higher highs into a new short-term high, but the sharp rally leaves it extended and prone to consolidation unless it breaks above $37.03.
Sharp rebound from $33.45 to $37.03 signals elevated short-term volatility risk
Sentiment & News
Key News Insights:
- •Jornay Growth
- •Azstarys Boost
- •Valuation Focus
Collegium Pharmaceutical's outlook has improved as strong Jornay PM growth and the Azstarys acquisition lifted guidance, shifting attention from earlier valuation concerns to strengthening revenue momentum.
The news is positive for COLL, as improving ADHD franchise growth and higher guidance should support investor sentiment and stock momentum
Similar Companies in Healthcare
Other companies in the same sector with AI ratings